| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3878902 | The Journal of Urology | 2007 | 10 Pages |
Abstract
Evolving data support a significant role for epigenetic processes in the development of prostate cancer and benign prostatic hyperplasia. Epigenetic changes can predict tumor behavior and often distinguish between genetically identical tumors. Targeted drugs that alter epigenetic modifications hold promise as a tool for curing and preventing these diseases.
Keywords
(-)-Epigallocatechin-3-gallateSAHAEGCGSAMHDACIGF2MTaseDAC5-aza-deoxycytidineHDACiPCAS-adenosylmethionineSuberoylanilide hydroxamic acidProstate cancerinsulin-like growth factor 2PhenylbutyrateHDAC inhibitorMethyltransferaseDNA methylationProstatic neoplasmsHistone acetyltransferasehistone deacetylaseBenign prostatic hyperplasiaBPHProstateGeneticsChromatinHAT
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Joseph R. Dobosy, J. Lea W. Roberts, Vivian X. Fu, David F. Jarrard,